| Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. | |
| | |
MedLine Citation:
|
PMID: 20849944 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
The brain is a major target of circulating insulin. Enhancing central nervous insulin action has been shown to improve memory functions in animals as well as in humans, benefitting in particular hippocampus-dependent (declarative) memory. As Alzheimer's disease (AD) is associated with reduced central nervous insulin signaling and attenuated permeation of blood-borne insulin across the blood-brain-barrier, the cognitive decline in AD patients may at least in part be derived from impaired brain insulin signaling. Thus, therapeutic strategies to overcome central nervous system insulin deficiency and resistance might be an attractive option in the treatment of cognitive impairments like AD. Insulin can be effectively delivered directly to the brain via the intranasal route that enables the hormone to bypass the blood-brain barrier and modulate central nervous functions. This review summarizes a series of studies demonstrating beneficial effects of intranasal insulin on memory functions both in healthy humans and in patients with cognitive impairments such as AD. These experiments in humans consistently indicate that enhancing brain insulin signaling by intranasal administration of the hormone improves hippocampus-dependent memory in the absence of adverse side effects. Considering that insulin also acts as a neuroprotective signal, up-regulating brain insulin levels by intranasal insulin administration appears to be a promising approach in the treatment and prevention of central nervous system insulin deficiency and resistance as found in AD. |
| | |
Authors:
|
Christian Benedict; William H Frey; Helgi B Schiöth; Bernd Schultes; Jan Born; Manfred Hallschmid |
Related Documents
:
|
20299484 - Progression of cerebral atrophy and white matter hyperintensities in patients with type... 12107744 - Up-regulation of glutamate receptors is associated with ltp defects in the early stages... 10671644 - Apolipoprotein e: a pharmacogenetic target for the treatment of alzheimer's disease. 9361934 - Preservation of pancreatic endocrine function by hemodynamic stabilization following br... 10382974 - Advanced glycation end-products in diabetic nephropathy. 6532934 - Different effects of metoclopramide and domperidone on gh release in type i male diabet... |
Publication Detail:
|
Type: Journal Article Date: 2010-09-16 |
Journal Detail:
|
Title: Experimental gerontology Volume: 46 ISSN: 1873-6815 ISO Abbreviation: Exp. Gerontol. Publication Date: 2011 Feb-Mar |
Date Detail:
|
Created Date: 2011-01-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0047061 Medline TA: Exp Gerontol Country: England |
Other Details:
|
Languages: eng Pagination: 112-5 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Neuroscience, University of Uppsala, Sweden; Department of Neuroendocrinology, University of Lübeck, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Enhancement of stress resistances and downregulation of Imd pathway by lower developmental temperatu...
Next Document: Emerging mitochondrial signaling mechanisms in physiology, aging processes, and as drug targets.